Metformin Auxilto (Metformin Hydrochloride)

Metformin reduces hepatic glucose production and enhances peripheral glucose uptake by activating AMP‑activated protein kinase (AMPK). This dual action lowers circulating blood glucose without stimulating insulin secretion, thereby improving overall insulin sensitivity.

The dose of Metformin Auxilto is individualized by the prescribing healthcare professional based on factors such as the patient’s renal function, glycaemic targets, concomitant medications, and tolerance. No fixed regimen is provided here.

Data on Metformin use during pregnancy are limited, and it is generally prescribed only when the potential benefits outweigh the risks. Breastfeeding mothers should consult their physician, as Metformin does pass into breast milk in small amounts.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin is a first‑line Biguanide that lowers glucose without causing weight gain and has a low risk of hypoglycaemia when used alone. Compared with sulfonylureas, it does not stimulate insulin release, and unlike insulin therapy, it is administered orally.

Store Metformin Auxilto at room temperature, ideally below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct heat, and discard any product that appears discoloured or damaged.

Metformin Auxilto is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water; crushing or chewing is not recommended unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that may present with muscle pain, rapid breathing, abdominal discomfort, or feeling unusually weak. Severe skin reactions such as Stevens‑Johnson syndrome and hepatic failure are also rare but critical concerns.

Metformin should be avoided in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those receiving iodinated contrast studies without appropriate discontinuation.